Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

A further presentation during the same symposium at AD/PD 2025 focused on how MRI methods could be accelerated to improve ...

Weight loss drugs such as semaglutide, found in Ozempic and Wegovy, are tied to a 40% reduced risk of an Alzheimer's disease ...

Encouraging interim results have supported Roche’s decision to move trontinemab into a pivotal Phase III programme.

Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

(Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...